Pursuant and subject to the terms of the Genentech License Agreement, Genentech has the exclusive worldwide right to conduct development and commercialization activities for Genentech Licensed Produc…
we have additionally entered into agreements with several CDMOs to provide us with preclinical and clinical trial materials for our non-ARCALYST assets
ARCALYST is sold through a third-party logistics provider that distributes primarily through a select network of specialty pharmacies (collectively, "customers"), which deliver the medication to pati…
In February 2022 we entered into two collaboration and license agreements (each, a "Huadong Collaboration Agreement" and together, the "Huadong Collaboration Agreements") with Huadong, pursuant to wh…
Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from KNSA graph: velop and commercialize ARCALYST worl…
velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos…
velop and commercialize ARCALYST worldwide, excluding the Middle East and North Africa, for all indications other than those in oncology and local administration to the eye or ear. Upon receiving pos…
y classified. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical and clinical development, process development and manufactur…
en they are labeled as free goods. The Company is conducting a technology transfer of ARCALYST drug substance manufacturing from Regeneron Pharmaceuticals, Inc. (“Regeneron”) to Samsung Biologics C…
